Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Celexa Heart Warnings Had No Effect on Prescribing Patterns: Study April 15, 2015 Irvin Jackson Add Your Comments The findings of new research suggest that FDA warnings about the risk of heart problems with Celexa have had very little impact on doctors’ habits with prescribing the antidepressant. In a study published in the medical journal The Primary Care Companion for CNS Disorders, researchers from Campbell University in North Carolina looked at medical records in the aftermath of a 2011 FDA warning on Celexa QT interval prolongation and found no observable change in how the medication was prescribed in the years that followed. Celexa (citalopram hydrobromide) was originally introduced in 1989 by Lundbeck, and is approved for the treatment of major depression. However, it is often used off-label to treat other psychological disorders. Celexa is available in brand name form or as a generic in 10 mg, 20 mg and 40 mg tablets, as well as a 10 mg/5 mL oral solution. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In August 2011, the FDA issued a warning that Celexa could cause prolongation of QT intervals at high doses. The FDA warned that the condition could lead to a serious and potentially fatal abnormal heart rhythm known as Torsade de Pointes. At the time, the Celexa label was updated to include the new warning and doctors were warned not to prescribe Celexa above 40 mg per day and not to use it at all in patients with congenital long QT syndrome. The agency also called on doctors to give patients taking Celexa more frequent electrocardiogram monitoring. However, according to this study, doctors do not appear to have received the message. Researchers collected data on 1,039 subjects with a mean age of nearly 73 years old, 447 of them whom were prescribed Celexa. They found that risk patterns, ranging from a scale of 0 to 7 in terms of QT prolongation risks, made no difference in who was prescribed Celexa, despite FDA urging doctors to consider such factors. However, they did find that the higher the risk factor, the higher the risk of QT prolongation. Dosing of Celexa appeared to have little effect, regardless of whether the patients were given 20 mg or higher doses. “In this sample of 447 medical inpatients 60 years of age or older prescribed citalopram at any dose, there was no significant difference in the percentage of subjects prescribed a daily dose of citalopram greater than 20 mg prior to and following the FDA alert,” the researchers noted. “There were also no statistically significant differences seen between groups in total number of risk factors pre- and post-FDA warning. A high percentage of subjects (98.8%) had at least 1 risk factor for QTc prolongation.” Lack of Prescriber Education Researchers said that it appears prescribers need more education to increase awareness about the potential Celexa heart risks and the overall risk of QT prolongation risk factors, such as heart failure, bradycardia, hypokalemia, and other factors when prescribing Celexa. They also need to be more aware of other heart drugs the patients might be taking and the risk of concomitant medications. They found that nearly 83% of the subjects in the study were also taking proarrhythmic medications, a number which appears to have actually gone up after the FDA’s warning. “One possibility is that prescribers are not recognizing concomitant proarrhythmic drugs, or they are unaware of the FDA warning regarding increased risk of QTc prolongation,” they wrote. “Another possibility is that prescribers generally reach for citalopram because it has been associated with lower rates of pharmacodynamic interactions, and they may be unaware of possible risks for QTc prolongation and torsades de pointes.” The study indicates that the only prescribing habit that changed for the positive was an increase in EKG monitoring, but said that was not enough and recommended a computerized alert system that would tag patients with potential risk factors like concomitant medications. “Given the risks of QTc prolongation with high-dose citalopram and the theoretical risk of torsades de points and sudden cardiac death, it is important to recognize and modify the risk factors,” the researchers concluded. ” Risk assessment tools and QTc alert systems have been implemented in other institutions and may be strategies to consider in institutions that have not yet adopted them.” Tags: Antidepressant, Celexa, Heart Rhythm, Lundbeck More Lawsuit Stories Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials April 2, 2025 Nitrous Oxide Class Action Lawsuit Filed Over Fatal Side Effects of Flavored Gas Sold In Vape Shops April 2, 2025 Artificial Stone Cutter Files Lawsuit Over Silicosis Lung Disease April 2, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: today) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025) Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: yesterday) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025) Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: 2 days ago) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)
Nitrous Oxide Class Action Lawsuit Filed Over Fatal Side Effects of Flavored Gas Sold In Vape Shops April 2, 2025
Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (Posted: today) As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025. MORE ABOUT: BIOZORB LAWSUITCourt Clears BioZorb Lawsuit Design Defect Claims Over Recalled Breast Tissue Marker (03/26/2025)Group of 7 BioZorb Injury Lawyers Appointed to Leadership Positions in Lawsuits Over Recalled Breast Tissue Marker (03/19/2025)Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (03/12/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: yesterday) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: 2 days ago) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)